Molecular Cancer Therapeutics · 2007 · 57 citations · 43 references
MedicineGeneticsOncologyMolecular OncologyNeoplasiaOncogenesCancer Molecular PathologyMalignant NeoplasmsOncogenic Signaling PathwaysSignal Transduction In CancerTargeted Cancer TherapyThyroid CancerB-raf InhibitorsBraf V600 MutationsBraf V600e MutationErk SignalingExtracellular Signal-regulated Kinase PathwayMitogen-activated Protein Kinase CascadesMitogen-activated Protein Kinase SignalingRaf-mek-erk Signaling
B-Raf is an important mediator of cell proliferation and survival signals transduced via the Ras-Raf-MEK-ERK cascade. BRAF mutations have been detected in several tumors, including papillary thyroid carcinoma, but the precise role of B-Raf as a therapeutic target for thyroid carcinoma is still under investigation. We analyzed a panel of 93 specimens and 14 thyroid carcinoma cell lines for the presence of BRAF mutations and activation of the mitogen-activated protein/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. We also compared the effect of a B-Raf small inhibitory RNA construct and the B-Raf kinase inhibitor AAL881 on both B-Raf wild-type and mutant thyroid carcinoma cell lines. We found a high prevalence of the T1799A (V600E) mutation in papillary and anaplastic carcinoma specimens and cell lines. There was no difference in patient age, B-Raf expression, Ki67 immunostaining, or clinical stage at presentation between wild-type and BRAF(V600E) specimens. Immunodetection of phosphorylated and total forms of MEK and ERK revealed no difference in their phosphorylation between wild-type and BRAF(V600E) patient specimens or cell lines. Furthermore, a small inhibitory RNA construct targeting the expression of both wild-type B-Raf and B-Raf(V600E) induced a comparable reduction of viability in both wild-type and BRAF(V600E) mutant cancer cells. Interestingly, AAL881 inhibited MEK and ERK phosphorylation and induced apoptosis preferentially in BRAF(V600E)-harboring cells than wild-type ones, possibly because of better inhibitory activity against B-Raf(V600E). We conclude that B-Raf is important for the pathophysiology of thyroid carcinomas irrespective of mutational status. Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
43
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
Ahmedin Jemal, Thomas S. Murray, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2005 · 5.5K citations · Full text
Marina N. Nikiforova, Edna Teruko Kimura, Manoj Gandhi et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 1.1K citations · Full text